Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
作者信息
Prébet Thomas, Gore Steven D, Thépot Sylvain, Esterni Benjamin, Quesnel Bruno, Beyne Rauzy Odile, Dreyfus François, Gardin Claude, Fenaux Pierre, Vey Norbert
出版信息
Br J Haematol. 2012 Jun;157(6):764-6. doi: 10.1111/j.1365-2141.2012.09076.x. Epub 2012 Mar 6.
Abstract
摘要
相似文献
1
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.阿扎胞苷治疗失败后骨髓增生异常综合征继发急性髓系白血病的预后
Br J Haematol. 2012 Jun;157(6):764-6. doi: 10.1111/j.1365-2141.2012.09076.x. Epub 2012 Mar 6.
2
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.阿扎胞苷用于80岁以上急性髓系白血病或骨髓增生异常综合征患者：115例患者的报告
Br J Haematol. 2020 Aug;190(3):461-464. doi: 10.1111/bjh.16680. Epub 2020 May 11.
3
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.不同阿扎胞苷剂量方案治疗骨髓增生异常综合征或急性髓系白血病患者的疗效和安全性。
Leuk Res. 2014 Jul;38(7):744-50. doi: 10.1016/j.leukres.2014.03.004. Epub 2014 Mar 19.
4
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.阿扎胞苷治疗失败后，骨髓增生异常综合征和急性髓系白血病对地西他滨缺乏客观反应。
Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.
5
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
6
The euphoria of hypomethylating agents in MDS and AML: is it justified?低甲基化药物在 MDS 和 AML 中的兴奋：这合理吗？
Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15.
7
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.阿扎胞苷对比利时高危骨髓增生异常综合征、急性髓系白血病或慢性粒单核细胞白血病患者的安全性和有效性：一项真实、非干预性上市后调查的结果
Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.
8
[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].5天阿扎胞苷治疗伴有复杂核型异常的骨髓增生异常综合征及急性髓系白血病
Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019.
9
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.高危骨髓增生异常综合征和继发性急性髓系白血病中对阿扎胞苷的反应与p53表达无关。
Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27.
10
Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials.
J Clin Oncol. 2014 Jan 1;32(1):60-1. doi: 10.1200/JCO.2013.52.5980. Epub 2013 Nov 18.
引用本文的文献
1
Analysis of chromatin accessibility associated with azacitidine response in higher-risk myelodysplastic neoplasms.高危骨髓增生异常肿瘤中与阿扎胞苷反应相关的染色质可及性分析
iScience. 2025 Aug 6;28(9):113297. doi: 10.1016/j.isci.2025.113297. eCollection 2025 Sep 19.
2
Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression.对继发性急性髓系白血病进展认识的最新进展
Life (Basel). 2024 Feb 27;14(3):309. doi: 10.3390/life14030309.
3
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Venetoclax 和 alvocidib 治疗复发/难治性急性髓系白血病患者的 1b 期研究。
Hematol Oncol. 2023 Oct;41(4):743-752. doi: 10.1002/hon.3159. Epub 2023 Apr 22.
4
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.骨髓增生异常综合征的治疗靶点：超越去甲基化药物
Curr Hematol Malig Rep. 2023 Jun;18(3):56-67. doi: 10.1007/s11899-023-00693-9. Epub 2023 Apr 13.
5
Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells.抑制DNMT3B以及PI3K/AKT/mTOR和ERK信号通路作为沃拉替尼对低甲基化剂耐药细胞作用的新机制
Biomol Ther (Seoul). 2023 May 1;31(3):319-329. doi: 10.4062/biomolther.2022.117. Epub 2022 Nov 16.
6
Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma.比较肿瘤学揭示 DNMT3B 是未分化多形性肉瘤的分子脆弱性。
Cell Oncol (Dordr). 2022 Dec;45(6):1277-1295. doi: 10.1007/s13402-022-00717-1. Epub 2022 Oct 1.
7
Identification of a prognostic model based on costimulatory molecule-related subtypes and characterization of tumor microenvironment infiltration in acute myeloid leukemia.基于共刺激分子相关亚型的急性髓系白血病预后模型的鉴定及肿瘤微环境浸润特征分析
Front Genet. 2022 Aug 19;13:973319. doi: 10.3389/fgene.2022.973319. eCollection 2022.
8
Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.脱氧核苷酸类似物的硅烷化生成具有抗白血病作用的口服药物。
Mol Cancer Ther. 2021 Aug;20(8):1412-1421. doi: 10.1158/1535-7163.MCT-20-1125. Epub 2021 May 27.
9
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.病例报告：异基因造血干细胞移植后接受 PD-1 阻断联合治疗导致致命移植物抗宿主病的急性髓系白血病。
Front Immunol. 2021 Apr 1;12:639217. doi: 10.3389/fimmu.2021.639217. eCollection 2021.
10
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.维奈托克和低甲基化剂（HMAs）可诱导 MDS 产生高缓解率，包括 HMA 治疗失败的患者。
Blood Adv. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482.
本文引用的文献
1
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.阿扎胞苷治疗失败后高危骨髓增生异常综合征的结局。
J Clin Oncol. 2011 Aug 20;29(24):3322-7. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.
2
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.骨髓增生异常综合征相关急性髓系白血病患者接受诱导化疗后的结果。
Cancer. 2011 Apr 1;117(7):1463-9. doi: 10.1002/cncr.25598. Epub 2010 Nov 8.
3
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.在 282 例接受阿扎胞苷治疗的高危骨髓增生异常综合征患者中，预测反应和总生存的预后因素。
Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.
4
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.阿扎胞苷相较于传统治疗方案可延长低骨髓原始细胞计数的老年急性髓系白血病患者的总生存期。
J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21.
5
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.在骨髓恶性肿瘤患者中，5-氮杂胞苷和恩替诺特重叠给药方案中，早期表观遗传变化和DNA损伤无法预测临床反应。
Blood. 2009 Sep 24;114(13):2764-73. doi: 10.1182/blood-2009-02-203547. Epub 2009 Jun 22.
6
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.阿扎胞苷与传统治疗方案治疗高危骨髓增生异常综合征的疗效比较：一项随机、开放标签的III期研究。
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
7
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.异常的DNA甲基化是骨髓增生异常综合征进展为急性髓系白血病的主要机制。
Blood. 2009 Feb 5;113(6):1315-25. doi: 10.1182/blood-2008-06-163246. Epub 2008 Oct 2.
8
Myelodysplastic syndromes.骨髓增生异常综合征
Blood. 2008 May 15;111(10):4841-51. doi: 10.1182/blood-2007-08-078139.
9
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.联合DNA甲基转移酶和组蛋白脱乙酰酶抑制用于治疗髓系肿瘤
Cancer Res. 2006 Jun 15;66(12):6361-9. doi: 10.1158/0008-5472.CAN-06-0080.
10
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.急性髓系白血病治疗试验的诊断、反应标准标准化、治疗结果及报告标准国际工作组修订建议
J Clin Oncol. 2003 Dec 15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036.
Zotero 插件